tirzepatide applewood Well Brain Body | Virtual

10.1016/j.cmet.2016.06.009 48 DruckerD

Highmark has published named anti-obesity policies (J-0184 for commercial weight-loss coverage, J-1370 for Medicare CV coverage), so prescribers know exactly what documentation is required

For instance, limiting coverage to those with higher BMI levels could mean forfeiting rebates and increasing cost per person treated

Side effects are typically mild and attributable to GLP-1 (nausea, constipation, appetite loss during dose escalation) rather than TRT interaction

In the Phase 2 obesity trial published in NEJM in 2023, retatrutide at the 12 mg weekly dose produced a mean placebo-adjusted body weight reduction of 22.1 percentage points (22.1% (24.2% arm) mean absolute reduction on the retatrutide arm) at 48 weeks (Jastreboff et al., NEJM, 2023)

How I Monitor Thyroid Patients on GLP-1 Heres what I look for: Labs: I monitor TSH, T3, and T4 to ensure your thyroid stays stable on GLP-1